Filing search / Kineta, Inc. / "Engagement"

Search information

Kineta, Inc.

Companies

"Engagement"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

103 results

Newest first Best match first

pursuant to the lease agreement. We have entered into an engagement letter with an investment bank whereby we may be obligated to pay certain fees … for financings and investment related transaction costs. This engagement letter expires on May 22, 2024. In addition, we enter into agreements

15 May 24

4:05pm

DEF 14A

KANT Kineta, Inc.

Definitive proxy

Committee. The terms and fees for the Company’s annual audit engagement are subject to specific pre-approval by the Audit Committee. Vote Required … controls contained in our periodic filings; pre-approving all audit and permitted non-audit services and related engagement fees and terms for services

26 Apr 24

4:00pm

biomarker of VISTA target engagement with KVA12123. VISTA-101 Initial Monotherapy Data Summary Safety Cleared first four KVA12123 monotherapy … also regularly surveys employees to assess employee engagement and satisfaction. The principal purposes of Kineta’s equity incentive plans

21 Mar 24

4:06pm

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

8:05am

engagement * p<0.05, ** p<0.01, *** p<0.001 Kineta data and analysis on file VISTA-101: KVA12123 demonstrated VISTA on-target immune cell responses

Kineta Announces Restructuring and Exploration of Strategic Alternatives

7:00am

the Effective Date (as defined below). (ii) Consulting Engagement. Subject to you returning an executed copy of the consulting agreement attached

Kineta Announces Restructuring and Exploration of Strategic Alternatives

Regulation FD Disclosure

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

3 Nov 23

4:04pm

Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Prospectus supplement for primary offering

Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy

11 Aug 23

4:07pm

10-Q

t33w66 p9

Quarterly report

11 May 23

5:22pm

DEF 14A

mjt8j4e646 jvyb9k

Definitive proxy

28 Apr 23

5:09pm

8-K

p9grakrxnl3

21 Apr 23

Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Prospectus supplement for primary offering

5:14pm

Filing search / Kineta, Inc. / "Engagement"

103 results

Top filers

Top filing types

Recent filing years